~~<i id='D6E5F843A7'><strike id='D6E5F843A7'><tt id='D6E5F843A7'><pre id='D6E5F843A7'></pre></tt></strike></i>~~

Home» focus» fashion

fashion

author：knowledge 2025-09-29 20:45:03 Page View：73574

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： A public scorecard can help hold safety
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

knowledge

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Medicare has a new plan to address drug shortages

Medicarehasanewproposaltopayhospitalsmoretostockpileessentialdrugs,anefforttoavoidshortagesofchemoth

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Medicare to cover more brain scans for Alzheimer’s patients

AnewlyapprovedAlzheimer’sdrugmadebyEisaiandBiogen,calledLeqembi,aimstoclearoutamyloidplaquesinpatien